Stocks and Investing
Stocks and Investing
Wed, August 14, 2024
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
Tue, August 13, 2024
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
Balaji Prasad Maintained (AMRX) at Buy with Increased Target to $10 on, Aug 13th, 2024
Balaji Prasad of Barclays, Maintained "Amneal Pharmaceuticals, Inc." (AMRX) at Buy with Increased Target from $8 to $10 on, Aug 13th, 2024.
Balaji has made no other calls on AMRX in the last 4 months.
There are 2 other peers that have a rating on AMRX. Out of the 2 peers that are also analyzing AMRX, 0 agree with Balaji's Rating of Hold.
These are the ratings of the 2 analyists that currently disagree with Balaji
- Les Sulewski of "Truist Securities" Maintained at Strong Buy with Increased Target to $10 on, Monday, August 12th, 2024
- Nathan Rich of "Goldman Sachs" Maintained at Strong Buy with Increased Target to $8 on, Monday, May 6th, 2024
Contributing Sources